



The 1st R-CCS International Symposium, Feb 18-19, 2019, Kobe, Japan


### Revealing Drug-Target Binding Pathway using Two-dimensional Replica-Exchange Molecular Dynamics Method

Suyong Re, Hiraku Oshima, Kento Kasahara, Motoshi Kamiya, and Yuji Sugita

Laboratory for Biomolecular Function Simulation RIKEN Center for Biosystems Dynamics Research (BDR)

*Priority Issue 1 – Building innovative drug discovery infrastructure through functional control of biomolecular systems (Sub-issue A: MD advancement and algorithms for the post-K) by MEXT* 

### **Molecular Dynamics, MD Simulation** For analyzing biomolecular dynamics and functions






Nobel Prize in Chemistry 2013 M. Karplus, M. Levitt, and A. Warshel "Development of multiscale models for complex chemical systems".

## **Evolution of MD Simulation**

Toward more realistic modeling, and longer timescale




(Slide from Dr. C. Kobayashi)



# GENESIS

Generalized-ensemble simulation system

### Highly scalable Enhanced sampling General purpose




Leader: Y. Sugita

Main developers: C. Kobayashi, J. Jung, Y. Matsunaga, T. Mori, T. Ando, K. Tamura, M. Kamiya

This is free software under GPLv2 License. https://www.r-ccs.riken.jp/labs/cbrt/ Current version: 1.3.0







J. Jung, T. Mori et al. WIREs Comput. Mol. Sci. 5, 310-323 (2015)


## Computational Drug Discovery

From "Docking" to "Binding"



Static shape complementarity






Y. Sugita and Y. Okamoto, Chem. Phys. Lett. 314:141-151 (1999)


## 2D-REMD for Ligand Binding

### Enhanced sampling of ligand-binding events


Multidimensional REMD: Y. Sugita, A. Kitao, and Y. Okamoto, J. Chem. Phys. 113: 6042-6051 (2000), MREM, REUS, H. Fukunishi, O. Watanabe, and S. Takada, J. Chem. Phys. 2002, 116 (20), 9058–9067, H-REMD First application: H. Kokubo et al. J. Comput. Chem. 34:2601-2614 (2013)



# Src Kinase – Inhibitor Binding A key signaling kinase in cancer process



#### ATP competitive inhibitor design based on the X-ray structure is limited



Only a part of whole functional interactions is given.

Thr338A Lys295A


Lys295A

Leu393A

Val281A

## **Three Essential States**

### Bound, TS, Encounter, Unbound states



gREST/REUS simulations provide atomic-level details of these states, we will discuss them in the presentation.

## Take-Home Message

MD simulations using enhanced sampling techniques as gREST/REUS can provide the information of **multiple bound poses, multiple intermediates, and multiple pathways** in protein-ligand bindings with high statistical accuracy.

The binding pathway information **provides the functional interactions that cannot be seen in the X-ray structures**, exploring new deign principle.


GENESIS on K and post-K computers would be a promising tool for next-generation drug discovery.

## Acknowledgement

### RIKEN Center for Biosystems Dynamics Research (BDR) Laboratory for Biomolecular Function Simulation

Dr. Yuji Sugita – Team leader Dr. Hiraku Oshima Dr. Kento Kasahara Dr. Motoshi Kamiya (IMS) Dr. Ai Niitsu (RIKEN Wako) Prof. Michael Feig (MSU, USA)

<u>About GENESIS usage</u> Dr. Jung Jaewoon Dr. Chigusa Kobayashi



Priority Issue 1 – Building Innovative drug discovery infrastructure through functional control of biomolecular systems (Sub-issue A: MD advancement and algorithms for the post-K)

Computational resources: K computer (Project ID: hp170254), FX10 in University of Tokyo (Project ID: hp170115) by HPCI system, and HOKUSAI (Project ID: G17016) by RIKEN Advanced Center for Computing and Communication.

# Thank you for your attention!